Innate Pharma (IPHA) Cash from Operations (2020 - 2024)
Historic Cash from Operations for Innate Pharma (IPHA) over the last 5 years, with Q4 2024 value amounting to -$7.4 million.
- Innate Pharma's Cash from Operations rose 7896.46% to -$7.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$74.4 million, marking a year-over-year increase of 4442.86%. This contributed to the annual value of -$7.4 million for FY2024, which is 7896.46% up from last year.
- According to the latest figures from Q4 2024, Innate Pharma's Cash from Operations is -$7.4 million, which was up 7896.46% from -$35.0 million recorded in Q4 2023.
- In the past 5 years, Innate Pharma's Cash from Operations ranged from a high of -$7.4 million in Q4 2024 and a low of -$66.9 million during Q4 2021
- In the last 5 years, Innate Pharma's Cash from Operations had a median value of -$36.3 million in 2021 and averaged -$38.1 million.
- In the last 5 years, Innate Pharma's Cash from Operations tumbled by 7925.51% in 2023 and then skyrocketed by 7896.46% in 2024.
- Innate Pharma's Cash from Operations (Quarter) stood at -$61.7 million in 2020, then decreased by 8.35% to -$66.9 million in 2021, then soared by 70.78% to -$19.5 million in 2022, then crashed by 79.26% to -$35.0 million in 2023, then surged by 78.96% to -$7.4 million in 2024.
- Its Cash from Operations was -$7.4 million in Q4 2024, compared to -$35.0 million in Q4 2023 and -$12.5 million in Q2 2023.